Suggestion for Research Design: Noninferiority Design in Elderly Patients With Soft-Tissue Sarcoma
- 1 March 2021
- journal article
- letter
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (7), 862-863
- https://doi.org/10.1200/jco.20.02907
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup StudyJournal of Clinical Oncology, 2020
- Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue SarcomasJAMA, 2020
- Methods of defining the non-inferiority margin in randomized, double-blind controlled trials: a systematic reviewTrials, 2017
- Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2015
- Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trialThe Lancet Oncology, 2014
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet, 2012
- Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)Journal of Clinical Oncology, 2009